openPR Logo
Press release

Peraso Inc. (NASDAQ: PRSO) Director Invests $127K, Ladenburg Thalmann Coverage, Gains Bullish Momentum

06-19-2024 08:08 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Peraso Inc. (NASDAQ: PRSO) Director Invests $127K, Ladenburg

On Tuesday, June 11th, Peraso Inc. (NASDAQ: PRSO) Director Ian McWalter acquired 100,000 shares of the company's stock at an average price of $1.27 per share, totalling $127,000. This strategic investment increases McWalter's holdings to 101,246 shares.

Image: https://www.abnewswire.com/uploads/9a500d398df4ec1d757968c73f802240.jpg

On June 12, 2024, Ladenburg Thalmann, a renowned Wall Street firm since 1876, initiated coverage [https://thestreetreports.com/wp-content/uploads/2024/06/PRSO-Updated-research.pdf] of Peraso Inc. (NASDAQ: PRSO). Research by Grandview Research in January 2024 highlighted the global mmWave market's growth to $3.75 billion in 2023. The study suggests that mmWave technology applications in consumer sectors could drive significant market expansion, potentially causing a paradigm shift and achieving a compound annual growth rate (CAGR) of around 40% through 2030. The mmWave technology market is expected to surpass $55 billion by the end of the decade, driven by the increasing use of bandwidth-intensive applications and the rising demand for high-speed IoT solutions. Founded in 2009, Peraso Inc. (NASDAQ: PRSO) has focused on mmWave solutions, establishing itself as the leading producer of mmWave devices and innovating high-volume mmWave production testing methodologies.

Ladenburg Thalmann states, "Considering the current size and anticipated rapid growth of the mmWave market, we believe Peraso's market-leading silicon and module solutions position the company for significant and sustained top- and bottom-line growth. We project a 22% revenue growth for 2024 and anticipate mmWave product revenue to increase by 160% year-over-year in 2025. With this expected growth, we value Peraso based on a multiple of 3x its estimated 2025 revenues, discounted back to the present at 20%. Therefore, we initiate coverage of Peraso Inc. (NASDAQ: PRSO) with a Buy rating and a 12-month price target of $3.75."

Peraso Inc. (NASDAQ: PRSO) shares opened at $1.50 on Friday. The stock has a twelve-month low of $1.17 and a 2024 high of $9.60, with a market cap of $4.01 million. It maintains a 50-day moving average of $1.37 and a 200-day moving average of $3.54. Recently, Peraso has shown multiple bullish indicators, reflected in a significant increase in trading volume over the past week, making it a stock to watch closely.

Pesaro Inc. NASDAQ: PRSO was recently featured with other MEME stocks trending tickers: GameStop (NYSE: GME). AMC Entertainment (NYSE: AMC), Novavax Inc. (NASDAQ: NVAX) Dyadic International Inc. (NASDAQ: DYAI), among others, [https://thestreetreports.com/meme-stocks-surge-led-by-roaring-kitty-and-social-media-buzz-on-reddit-nyse-rddt-gme-dyai-amc-prso-nvax/]

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=peraso-inc-nasdaq-prso-director-invests-127k-ladenburg-thalmann-coverage-gains-bullish-momentum]
Country: United States
Website: http://www.thestreetreports.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Peraso Inc. (NASDAQ: PRSO) Director Invests $127K, Ladenburg Thalmann Coverage, Gains Bullish Momentum here

News-ID: 3545398 • Views:

More Releases from ABNewswire

RINVOQ Market Growth Accelerates Across IBD, Dermatology, and Rheumatology as Global Sales Momentum Strengthens | DelveInsight
RINVOQ Market Growth Accelerates Across IBD, Dermatology, and Rheumatology as Gl …
The global immunology market is witnessing a significant transformation as RINVOQ (upadacitinib) continues to demonstrate strong prescription growth, expanding indications, and robust revenue performance. DelveInsight's "RINVOQ Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of RINVOQ for approved indications like Ankylosing Spondylitis, Atopic Dermatitis, Axial SpA, Crohn's Disease, Giant Cell Arteritis, Psoriatic Arthritis, Rheumatoid Arthritis, and Ulcerative Colitis; as well as potential indications like Alopecia Areata, Hidradenitis
Prostate Cancer Competitive Landscape Analysis 2026: Clinical Trial Trends, Novel Therapies, Regulatory Milestones, and Future Outlook | DelveInsight
Prostate Cancer Competitive Landscape Analysis 2026: Clinical Trial Trends, Nove …
Leading Prostate Cancer companies include Merck & Co., Inc., Telix Pharmaceuticals Limited, Exelixis, Inc., AstraZeneca PLC, Pfizer Inc., Bristol-Myers Squibb Company, AbbVie Inc., BeiGene, Ltd., and Ipsen S.A., among many others-are actively developing next-generation therapies to reshape the treatment landscape. The treatment paradigm for prostate cancer is witnessing rapid transformation, with more than 150 companies advancing innovative drug candidates across diverse clinical phases. Recent milestones include multiple FDA fast-track designations, companion
Electrosurgical Devices Market to Reach USD 10,220.04 Million by 2034, Growing at 6.34% CAGR | DelveInsight
Electrosurgical Devices Market to Reach USD 10,220.04 Million by 2034, Growing a …
Electrosurgical Devices Companies in the market include B. Braun Melsungen AG, ConMed Corporation, Olympus Corporation, Apyx Medical Corporation, Medtronic, Johnson & Johnson, Smith & Nephew Plc, Erbe Elektromedizin GmbH, KLS Martin Group, BOWA-electronic GmbH & Co. KG, Modern Medical, Kirwan Surgical Products, LLC, Utah Medical Products, Inc., Hangzhou AGS MedTech Co., Ltd., New Deantronics Taiwan Ltd., Parkell, Inc., Surgical Holdings, CIMPAX, Boston Scientific Corporation, and Others The global electrosurgical devices market
Hypertension Treatment Pipeline Shows Strong Momentum as 80+ Pharma Companies in the Race | DelveInsight
Hypertension Treatment Pipeline Shows Strong Momentum as 80+ Pharma Companies in …
DelveInsight's, "Hypertension Pipeline Insight, 2026" report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Hypertension pipeline landscape. It covers the Hypertension pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hypertension pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in

All 5 Releases


More Releases for Peraso

Undervalued Tech: Peraso Inc's (NASDAQ: PRSO) True Value Signals Upside - More S …
Mobix Labs recently made the kind of mistake that reveals more about the bidder than the target. Their unsolicited acquisition [https://www.stocktitan.net/news/PRSO/peraso-confirms-receipt-of-unsolicited-non-binding-acquisition-pevb9rjomb71.html] offer for Peraso represents classic bottom-feeding behavior. A 20% premium that exploits market pressure rather than recognizing strategic value. This follows their established pattern of lowball offers to multiple companies. Mobix declined to sign standard confidentiality agreements, indicating they never intended serious due diligence. The timing reveals everything. PerasoInc's (NASDAQ:
Peraso Inc. (NASDAQ: PRSO) Signals Turnaround - Reports Financials August 11, 20 …
Peraso Inc. (NASDAQ: PRSO) a fundamental growth story-driven by military contracts, commercial wins, and sector diversification-is even more compelling. Over the past year, Peraso has strategically expanded its footprint, building a foundation for long-term growth powered by its proprietary 60GHz mmWave technology. Defense Sector: Stealthy Solutions for Modern Battlefields Peraso Inc.'s (NASDAQ: PRSO) entry into the defense sector marks a key inflection point, with its Perspectus module-featuring stealth, low-jamming, narrow-beamforming, and week-long
Peraso (NASDAQ: PRSO) Volume Surges on Takeover News - More Stocks Inside
Mobix Labs, Inc. (NASDAQ: MOBX) has launched an unsolicited, non-binding proposal to acquire Peraso Inc. (NASDAQ: PRSO) in a stock-for-stock deal offering Peraso shareholders a 20% premium over the company's 30-day average share price. The proposed merger would create a stronger player in the high-growth mmWave, defense, and 5G semiconductor sectors-combining Mobix's $10.7M revenue base and ~450% YoY growth with Peraso's accelerating mmWave performance. The combined company is expected to generate
Peraso Inc.'s (NASDAQ: PRSO) Beamforming Technology Gains Military Traction - Se …
Peraso Inc.'s (NASDAQ: PRSO) advanced beamforming technology has proven to be a game-changer in military and dense urban deployments, where secure, reliable, and high-performance communication is critical. Beamforming's ability to direct signals with precision and bend them around obstacles not only maximizes efficiency but also makes transmissions exceptionally difficult to detect or intercept. These stealth capabilities, combined with Peraso's proprietary innovations, have enabled its solutions to excel in active war
Peraso Inc.'s (NASDAQ: PRSO) PERSPECTUS Modules Outperform in 60Ghz FWA Market
Introduction As high-speed internet access spreads around the world, the unlicensed 60GHz (57-71 Ghz) millimeter-wave (mmWave) spectrum offers immense potential for low-cost, low-capex, easily-deployed high-speed wireless communication, especially areas currently underserved by traditional broadband distribution-fiberoptic. Further, However, until recently, purchasing devices to adequately provide mmWave communications for 60Ghz/mmWave broadband deployments has been difficult. Peraso and several other companies have developed and ramped up mass manufacturing of viable 60Ghz solutions for this
Spotlight: Peraso Inc. (NASDAQ: PRSO) A Semiconductor Valued Stock In Focus
Peraso Inc. (NASDAQ: PRSO), a prominent player in mmWave technology for 5G licensed and 60 GHz unlicensed networks, disclosed its financial outcomes for the initial fiscal quarter concluding on March 31, 2024, on May 13. The company revealed total net earnings of $2.8 million, contrasting with $1.8 million in the preceding quarter and $5 million in the corresponding period of the prior year. Image: https://www.abnewswire.com/uploads/ab52a2e3727e2c3a192fc9b4209229c4.jpg During the first quarter, product revenues amounted